Court dismisses United Therapeutics' claim against Liquidia's YUTREPIA NDA, allowing potential final approval post-regulatory exclusivity expiration in 2025. The U.S. District Court dismissed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results